A phase IB/IIA study of remestemcel-L, an allogeneic bone marrow-derived mesenchymal stem cell product, for the treatment of medically refractory ulcerative colitis: an interim analysis.

Amy L LightnerNeda DadgarCaroline MatyasKavita ElliottClifton FulmerNeha KhaitanJustin ReamDouglas NachandScott R Steele

Published in: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2022)

MSCs may offer a safe therapeutic option for the treatment of medically refractory UC. Early data suggest improved clinical and endoscopic scores by 2 weeks after MSC delivery.

Keyphrases

mesenchymal stem cells
ulcerative colitis
bone marrow
stem cell transplantation
stem cells
electronic health record
machine learning
replacement therapy
preterm birth